Salarius Pharmaceuticals, Inc. (SLRX) Reports Q2 Loss of $1.43
Tweet
Share
E-mailGet Alerts SLRX Hot Sheet
Join SI Premium – FREE
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) reported Q2 EPS of ($1.43).
For earnings history and earnings-related data on Salarius Pharmaceuticals, Inc. (SLRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Femcare acquires UK harm reduction firm Orion for £3.6M
- KeyBanc on National Fuel Gas (NFG): 'P&S Growth an Underappreciated Hedge to Weak Natural Gas Prices'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
